Clinical Trial Update: S0902 Bendamustine and Rituximab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Not Responded to Previous Treatment [Phase 2]

View source ↗

Summary

A Phase 2 trial of bendamustine plus rituximab for B-cell chronic lymphocytic leukemia that has not responded to prior treatment has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Rituxan (rituximab)
• Treanda (Bendamustine)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Leukemia | Phase 2 | Status: WITHDRAWN